Skip to main content
Premium Trial:

Request an Annual Quote

Lion s Q3 Revenues Surge, Net Losses Narrow

NEW YORK, Feb 7 – Lion Bioscience said Wednesday its fiscal third quarter 2001 revenues more than doubled to 7.7 million euros ($7.1 million), compared with 2.9 million euros in the year ago period, as research and development as well as licensing fees increased.

In the third quarter, revenues from research and development fees shot up 161 percent to 4.7 million euros, while licensing fees increased to 2.9 million euros from 1.1 million euros in the corresponding period a year ago.

At the same time, however, total costs and expenses doubled, rising to 12.0 million euros in the third quarter, compared with 6.0 million euros a year ago. The increase in costs stemmed from higher R&D expenses as well as greater selling, general, and administrative expenses.

As a result, the third quarter losses from operations widened by 39 percent to 4.3 million euros, compared with operating losses of 3.1 million euros in the year ago period.

During the quarter, Lion of Heidelberg formed alliances with Celera and Bayer and acquired Trega Biosciences, a cheminformatics company based in San Diego.

Celera now uses Lion’s SRS technology as the base technology for its Celera Discovery System. With Bayer, Lion expanded into the field of pharmacophore informatics, and the merger with Trega combined the two companies’ drug discovery and data analysis capabilities.

Net losses for the third quarter narrowed to 2.2 million euros, compared with net losses of 3.0 million euros in the year-ago quarter. The company did not disclose the loss per share.

In January, Lion released ArrayScout 2.0, an updated version of it gene expression data analysis system.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.